The Journal of Bone and Joint Surgery (American). 2006;88:273-281.
doi:10.2106/JBJS.D.02738
© 2006 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the exams for this article:
 Pain Management Test 4: Winter 2008 (publication date February 15, 2008; ex...
Pain Management Test 3: Spring 2006 (publication date May 15, 2006; expirat...
CME 1: January, February, March 2006
Right arrow [Supplementary Material]
Right arrow Letters to the Editor: Submit a response
Right arrow Letters to the Editor: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JBJS
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hartrick, C. T.
Right arrow Articles by Manvelian, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartrick, C. T.
Right arrow Articles by Manvelian, G.
Related Collections
Right arrow Pain Management
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?

Evaluation of a Single-Dose, Extended-Release Epidural Morphine Formulation for Pain After Knee Arthroplasty

Craig T. Hartrick, MD1, Gavin Martin, MD2, George Kantor, MD3, John Koncelik, DO4 and Garen Manvelian, MD5

1 Department of Anesthesia, William Beaumont Hospital, 3601 West 13 Mile Road, Royal Oak, MI 48073. E-mail address: chartrick{at}beaumont.edu
2 Department of Anesthesiology, Duke University Medical Center, P.O. Box 3094, Erwin Road, Room 3438 Duke North, Durham, NC 27710
3 Palm Beach Gardens Medical Center, 11211 Prosperity Farms Road, Suite C114, Palm Beach Gardens, FL 33410-3454
4 Sewickley Valley Hospital, 720 Blackburn Road, Sewickley, PA 15143
5 SkyePharma, Inc., 10450 Science Center Drive, San Diego, CA 92121

In support of their research for or preparation of this manuscript, one or more of the authors received grants or outside funding from SkyePharma, Inc., San Diego, California. In addition, one or more of the authors received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity (SkyePharma, Inc.). Also, a commercial entity (SkyePharma, Inc.) paid or directed, or agreed to pay or direct, benefits to a research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.

Background: DepoDur is a single-dose, extended-release epidural morphine formulation designed to provide forty-eight hours of pain relief. The drug offers potential advantages over continuous epidural infusions, particularly in patients being treated with anticoagulation therapy. The purpose of this study was to evaluate the efficacy and safety of single-dose epidural DepoDur for pain control following knee arthroplasty.

Methods: In this multicenter, randomized, double-blind, parallel-group study, patients were randomized to receive a single-dose of DepoDur (20 or 30 mg) or a sham epidural injection thirty minutes before administration of general or regional anesthesia for knee arthroplasty. At their first request for postoperative analgesia, patients who had received DepoDur were given an intravenous bolus of hydromorphone followed by placebo patient-controlled analgesia. Patients who had received the sham epidural were given an intravenous bolus of morphine followed by patient-controlled analgesia with morphine. Patient ratings of pain intensity at rest and with activity, their rating of overall pain control, and postoperative opioid use were recorded. The ability to tolerate physical therapy, the range of motion of the knee, and the need for physical support were assessed as well. Adverse events and vital signs were recorded.

Results: Of 168 patients randomized to receive the 20-mg injection of DepoDur, the 30-mg injection of DepoDur, or the sham epidural injection, fifty-one, fifty-eight, and fifty-five patients, respectively, were included in the efficacy analysis. Compared with the patients treated with intravenous patient-controlled analgesia with morphine, the patients treated with DepoDur had significantly reduced mean pain-intensity-recall scores during the four to eight, four to twelve, four to twenty-four, and four to thirty-hour postdose intervals (p < 0.05 for all comparisons). The patients treated with DepoDur used approximately a threefold lower amount of postoperative opioids in total, with a significant percentage requiring no supplemental opioids. Adverse events common to all groups were nausea (78%), pyrexia (46%), vomiting (43%), pruritus (43%), and hypotension (36%). Respiratory depression was the most common serious adverse event, with serious respiratory depression observed in four DepoDur-treated patients, who were more than sixty-five years of age.

Conclusions: With appropriate patient selection and monitoring, perioperative single-dose epidural DepoDur was a safe and effective analgesic alternative to postoperative intravenous patient-controlled analgesia following knee arthroplasty, with younger patients benefiting from the 20-mg dose. Additional studies of 10 to 15-mg doses for older patients are warranted.

Level of Evidence: Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?

Related articles in JBJS:

Evaluation of a Single-Dose, Extended-Release Epidural Morphine Formulation for Pain After Knee Arthroplasty
André P. Boezaart
JBJS 2006 88: 2535-2536. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. N. Macias, T. G. Hall, and J. Ostlund
Extended-release epidural morphine and postoperative nausea or vomiting
Am. J. Health Syst. Pharm., February 1, 2008; 65(3): 200 - 200.
[Full Text] [PDF]

Home page
 JBJSHome page
J. H. Lonner and C. A. Deirmengian
What's New in Adult Reconstructive Knee Surgery
J. Bone Joint Surg. Am., December 1, 2007; 89(12): 2828 - 2837.
[Full Text] [PDF]

Home page
 JBJSHome page
H. N. Herkowitz, D. R. Dirschl, and D. H. Sohn
Pain Management: The Orthopaedic Surgeon's Perspective
J. Bone Joint Surg. Am., November 1, 2007; 89(11): 2532 - 2535.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
B. Carvalho, L. M. Roland, L. F. Chu, V. A. Campitelli III, and E. T. Riley
Single-Dose, Extended-Release Epidural Morphine (DepoDurTM) Compared to Conventional Epidural Morphine for Post-Cesarean Pain
Anesth. Analg., July 1, 2007; 105(1): 176 - 183.
[Abstract] [Full Text] [PDF]

Letters to the Editor:

Read all Letters to the Editor

Extended Release Epidural Morphine
André P. Boezaart, M.B.Ch.B., FFA(CMSA, MMed(Anaesth), Ph.D. Professor
JBJS Online, 24 May 2006 [Full text]
Dr. Hartrick et al reply to Dr. Boezaart
Craig T. Hartrick, M.D., DABPM, FIPP, et al.
JBJS Online, 24 May 2006 [Full text]